Skip Navigation

European Heart Journal 1997 18(Supplement D):24-30; doi:10.1093/eurheartj/18.suppl_D.24
Copyright © 1997 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ketteler, T.
Right arrow Articles by Gülker, H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ketteler, T.
Right arrow Articles by Gülker, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1997 The European Society of Cardiology

Arbutamine stress echocardiography

T. Ketteler, W. Krahwinkel, J. Wolfertz, J. Gödke, T. Hoffmeister, L. Scheuble and H. Gülker

Wuppertal Heart Center, Department of Cardiology, University of Witten/Herdecke Wuppertal, Germany

Correspondence: Dr T. Ketteler, Klinikum Wuppertal GmbH, Medizinische Klinik B. Schwerpunkt Kardiologie, Heusnerstr. 40, 42283 Wuppertal, Germany

Arbutamine, a new potent non-selective β-adrenoceptor agonist with mild {alpha}1-sympathomimetic activity, has been developed specifically for pharmacological stress testing. The drug acts like physical exercise, increasing both heart rate and myocardial contractility. Sensitivity, specificity and accuracy in detecting significant stenotic coronary artery disease are 76%, 96%, and 82%, respectively, agian similar to those of exercise echocardiography.

The drug is delivered by a computerized drug delivery and monitoring device (GenESA) which adjusts the infusion rate according to the patient's heart rate data feedback. The drug is generally well tolerated and has an acceptable safety profile.

This article describes recent clinical experience with arbutamine and presents preliminary results of a multicentre multinational study which evaluates the clinical utility and safety of the GenESA system in diagnosing coronary artery disease.

Key Words: Arbutamine • stress echocardiography • coronary artery disease • ischaemia


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
W. J. Cantor, A. S. Hellkamp, E. D. Peterson, J. P. Zidar, P. A. Cowper, M. H. Sketch Jr, J. E. Tcheng, R. M. Califf, and E. M. Ohman
Achieving optimal results with standard balloon angioplasty: can baseline and angiographic variables predict stent-like outcomes?
J. Am. Coll. Cardiol., June 1, 2001; 37(7): 1883 - 1890.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
W. J. Cantor, E. D. Peterson, J. J. Popma, J. P. Zidar, M. H. Sketch Jr., J. E. Tcheng, and E. M. Ohman
Provisional stenting strategies: systematic overview and implications for clinical decision-making
J. Am. Coll. Cardiol., October 1, 2000; 36(4): 1142 - 1151.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.